

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: HEIGHTMAN et al.

Confirmation No.: 2093

U.S. Serial No.: 10/599,636

Art Unit: 1624

Filing Date: October 4, 2006

Examiner: Coleman, Brenda L

Title: Tetrahydrobenzazepines as Histamine H3 Receptor Ligands

COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, VA 22313-1450

LETTER

Sir:

In the above-identified case, Applicant wants to make the US Patent Office aware of the following co-pending applications:

US Serial No.	US Filing Date	Attorney Docket No.
10/539,385	12/18/03	P33159
11/831,191	7/31/07	P33159 D1
12/339,145	12/19/08	P33159 D3
10/596,503	12/15/04	PB60626
10/598,759	3/10/05	PB60780
11/570,383	6/16/05	PB60910
11/573,732	8/12/05	PB61014

The following PCT cases of Applicant are also pending: WO 2008/104,598 and WO 2008/104,590.

Respectfully submitted,

Bonnie L. Deppenbrock

Bonnie L. Deppenbrock
Attorney for Applicant
Registration No. 28,209

Date: 16 June 2009

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

Five Moore Drive

P.O. Box 13398

Research Triangle Park, NC 27709-3398

Phone: 919-483-1577

Facsimile: 919-483-7988

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : HEIGHTMAN, et al.
Serial No. : 10/599,636
Filing Date : October 4, 2006
Title : TETRAHYDROBENZAZEPINES AS HISTAMINE H3 RECEPTOR LIGANDS

Grp. /A.U. : 1624
Examiner : Coleman, Brenda Libby
Confirmation No. : 2093

Docket No. : PB60825USw

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the following references are enclosed. **References 1-11**
☐ Copies of the references were submitted in parent application Serial No. _____. (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☒ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**

- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and

- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No. **07-1392**.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,

Bonnie L. Deppenbrock

Bonnie L. Deppenbrock, Attorney of Record
Registration No. 28,209

Date: 16 June 2009
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-1577
Facsimile: (919) 483-7988